X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (103) 103
middle aged (84) 84
female (78) 78
aged (73) 73
male (73) 73
adult (61) 61
oncology (58) 58
index medicus (40) 40
aged, 80 and over (35) 35
cancer (27) 27
prognosis (22) 22
article (21) 21
hematology (20) 20
surgery (20) 20
retrospective studies (19) 19
adolescent (18) 18
carcinoma (17) 17
survival rate (17) 17
treatment outcome (17) 17
adenocarcinoma (15) 15
chemotherapy (14) 14
expression (14) 14
multivariate analysis (14) 14
disease-free survival (13) 13
hematology, oncology and palliative medicine (13) 13
survival (13) 13
transplantation (13) 13
immunohistochemistry (12) 12
dna methylation (11) 11
obstetrics & gynecology (11) 11
pathology (11) 11
research (11) 11
tumors (11) 11
care and treatment (10) 10
child (10) 10
cyclophosphamide (10) 10
follow-up studies (10) 10
ovarian cancer (10) 10
survival analysis (10) 10
young adult (10) 10
cyclophosphamide - administration & dosage (9) 9
neoplasm staging (9) 9
prostate cancer (9) 9
radiotherapy (9) 9
risk factors (9) 9
therapy (9) 9
analysis (8) 8
mortality (8) 8
obstetrics and gynecology (8) 8
ovarian neoplasms - surgery (8) 8
proportional hazards models (8) 8
abridged index medicus (7) 7
animals (7) 7
bone marrow (7) 7
bone marrow transplantation - adverse effects (7) 7
bone-marrow-transplantation (7) 7
combined modality therapy (7) 7
disease (7) 7
dose-response relationship, drug (7) 7
immunology (7) 7
progression (7) 7
prostatic neoplasms - pathology (7) 7
transplantation, homologous (7) 7
acute myeloid-leukemia (6) 6
adenocarcinoma - pathology (6) 6
carcinoma, squamous cell - genetics (6) 6
cells (6) 6
child, preschool (6) 6
dna (6) 6
head and neck neoplasms - genetics (6) 6
immunotherapy (6) 6
logistic models (6) 6
lung-cancer (6) 6
mice (6) 6
prospective studies (6) 6
solid tumors (6) 6
stem-cell transplantation (6) 6
trial (6) 6
versus-host-disease (6) 6
acute disease (5) 5
antigen (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
biomarkers, tumor - genetics (5) 5
breast-cancer (5) 5
cisplatin (5) 5
disease progression (5) 5
double-blind method (5) 5
gene expression regulation, neoplastic (5) 5
head and neck cancer (5) 5
health aspects (5) 5
leukemia (5) 5
mutations (5) 5
otorhinolaryngology (5) 5
ovarian carcinoma (5) 5
ovarian neoplasms - pathology (5) 5
p53 (5) 5
pancreatic neoplasms - mortality (5) 5
patients (5) 5
prostatic neoplasms - drug therapy (5) 5
radiation (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4027 - 4034
Purpose: Pazopanib, a multireceptor tyrosine kinase inhibitor targeting primarily VEGFRs1-3, is approved for advanced soft tissue sarcoma (STS) and renal cell... 
EWINGS-SARCOMA | CELLS | SOLID TUMORS | ONCOLOGY | PATHWAY | THYROID-CANCER | PALETTE | GROWTH | RHABDOMYOSARCOMA | RESISTANCE | SORAFENIB | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Pyrimidines - administration & dosage | Humans | Middle Aged | Pyrimidinones - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Sarcoma - drug therapy | Sarcoma - pathology | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Pyridones - administration & dosage | Drug-Related Side Effects and Adverse Reactions | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Adult | Female | Aged | Pyrimidinones - administration & dosage | Sarcoma - genetics | MAP Kinase Kinase Kinase 1 - antagonists & inhibitors | Pyridones - adverse effects | Sulfonamides - administration & dosage | Rhabdomyosarcoma | Raf protein | Synergism | Metastases | Confidence intervals | Safety engineering | Vascular endothelial growth factor | Protein-tyrosine kinase | Tyrosine | Kidneys | Sarcoma | Melanoma | Soft tissue sarcoma | Diarrhea | Fatigue | Nausea | Disease control | Survival | Patients | Vascular endothelial growth factor receptors | Inhibitors | Experimental design | Aberration | Clear cell-type renal cell carcinoma | Cancer
Journal Article
British Journal of Cancer, ISSN 0007-0920, 05/2017, Volume 116, Issue 11, pp. 1402 - 1407
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 06/2019
Differentiated thyroid cancer (DTC) responds to VEGF receptor inhibitors. VEGF signals through RAS/RAF/MEK signaling. We evaluated the safety and efficacy of... 
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2000, Volume 92, Issue 9, pp. 709 - 720
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2005, Volume 23, Issue 36, pp. 9338 - 9343
Purpose To evaluate the risk of epithelial ovarian cancer (EOC) recurrence in patients with rising serum cancer antigen 125 (CA-125) levels that remain below... 
ASSAY | ULTRASOUND | ONCOLOGY | CA125 | MARKERS | MONOCLONAL-ANTIBODY | PREOPERATIVE DIAGNOSIS | CARCINOMA | MENOPAUSAL STATUS | PROGRESSION | ANTIGEN | CA-125 Antigen - blood | Humans | Middle Aged | Risk Factors | Neoplasm Recurrence, Local | Ovarian Neoplasms - pathology | Reference Values | Biomarkers, Tumor - blood | Adult | Female | Aged | Retrospective Studies | Odds Ratio
Journal Article
Cancer, ISSN 0008-543X, 03/2012, Volume 118, Issue 6, pp. 1533 - 1542
BACKGROUND: Several phase II trials in men with noncastrate PSA‐recurrent prostate cancer have assessed the impact of novel nonhormonal agents on PSA kinetics.... 
prostate cancer | metastasis‐free survival | PSA slope | PSA doubling time | PSA recurrence | PSA velocity | PSA kinetics | BIOCHEMICAL RECURRENCE | RISK | RADICAL PROSTATECTOMY | NATURAL-HISTORY | ANDROGEN-DEPRIVATION THERAPY | ONCOLOGY | metastasis-free survival | RECOMMENDATIONS | CLINICAL-TRIALS | CARDIOVASCULAR-DISEASE | PROGRESSION | ANTIGEN
Journal Article
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 09/2019, Volume 25, Issue 18, pp. 5475 - 5484
Purpose: Differentiated thyroid cancer (DTC) responds to VEGF receptor inhibitors. VEGF signals through RAS/RAF/MEK signaling. We evaluated the safety and... 
DABRAFENIB | PLACEBO | MELANOMA | ONCOLOGY | PATHWAY | SELUMETINIB | BRAF | CARCINOMA
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.